Publications by authors named "Ross Hearn"
Article Synopsis
- The study compares the real-world effectiveness and safety of three treatments for atopic dermatitis: dupilumab, ciclosporin (CyA), and methotrexate (MTX), using data from the A-STAR register in the UK and Ireland.
- It involved 488 patients (adults and children) and measured treatment outcomes like the Eczema Area and Severity Index (EASI) and quality of life scales over 12 months.
- Results showed that dupilumab and CyA led to faster improvements in skin severity scores and overall patient outcomes compared to MTX, indicating dupilumab is an effective option in managing atopic dermatitis.
Article Synopsis
- A study compared the safety and effectiveness of ciclosporin (CyA) and methotrexate (MTX) in treating severe atopic dermatitis (AD) in children and young people aged 2-16 who didn't respond to topical treatments.
- Cyclists showed more significant improvement at the 12-week mark, with more patients achieving at least a 50% improvement in their AD scores compared to those on MTX.
- However, by the 60-week follow-up, MTX demonstrated better long-term outcomes, indicating its potential superiority beyond the initial treatment period.
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease. Sodium cromoglicate (SCG) is a chromone with anti-inflammatory, anti-itch and anti-allergic activity. This trial is a 12-week comparison (RCT) of a 4% SCG cutaneous emulsion with its vehicle in AD.
View Article and Find Full Text PDFIs the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid?
Photodermatol Photoimmunol Photomed
October 2012
Topical photodynamic therapy (PDT) using 5-aminolaevulinic acid (ALA) or methyl aminolevulinate (MAL) is widely used in dermatology. It is commonly stated that MAL PDT is less painful than ALA PDT, although published data are conflicting. We report our experience of the use of ALA (4-6 h) (n = 20) and MAL (3 h) (n = 20) in 40 consecutive patients with Bowen's disease or superficial basal cell carcinoma, treated with PDT using an identical irradiation regime.
View Article and Find Full Text PDF